The Scotland-based company develops a novel pop-up cardboard dry powder inhaler (DPI). Rather than use expensive, bulky plastic, 1nhaler uses cardboard to create an inhaler with the same dimensions as a credit card. The discreet platform features a breathable membrane capable of tailoring to deliver individual drugs to patients.
With the latest fundraising, the company adds to $2.5 million brought in nearly two years ago. Archangels led the round, while Scottish Enterprise and BBB Investments supported it.
The investment enables 1nhaler to advance its platform toward a first marketing authorization application (MAA) in Europe. It targets late 2027 for that milestone. This includes the manufacture of clinical material for regulatory studies and the design of large-scale commercial manufacturing processes.
1nhaler said inhalable medicines already treat conditions like asthma, COPD, influenza, anaphylaxis, epilepsy, depression and Parkinson’s. It believes its unique, single-dose DPI platform can address key limitations in current deliver options, including accessibility, cost, performance and environmental impact.
“This additional funding represents strong continued confidence in our technology platform and our progress towards commercialization. The support from Archangels, Scottish Enterprise and BBB Investments is enabling us to advance our clinical and manufacturing capabilities as we work towards regulatory approval,” said Lisa McMyn, co-founder and CEO of 1nhaler. “Our platform has the potential to become the simplest, most convenient single-dose, disposable inhaler on the market, transforming the delivery of inhalable drugs without the cost and environmental impact of existing devices.”
